Enduring neurological sequelae of benzodiazepine use: an Internet survey
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Introduction: Benzodiazepine tapering and cessation has been associated with diverse symptom constellations of varying duration. Although described in the literature decades ago, the mechanistic underpinnings of enduring symptoms that can last months or years have not yet been elucidated. Objective: This secondary analysis of the results from an Internet survey sought to better understand the acute and protracted withdrawal symptoms associated with benzodiazepine use and discontinuation. Methods: An online survey ( n = 1207) was used to gather information about benzodiazepine use, including withdrawal syndrome and protracted symptoms. Results: The mean number of withdrawal symptoms reported by a respondent in this survey was 15 out of 23 symptoms. Six percent of respondents reported having all 23 listed symptoms. A cluster of least-frequently reported symptoms (whole-body trembling, hallucinations, seizures) were also the symptoms most frequently reported as lasting only days or weeks, that is, short-duration symptoms. Symptoms of nervousness/anxiety/fear, sleep disturbances, low energy, and difficulty focusing/distractedness were experienced by the majority of respondents (⩾85%) and, along with memory loss, were the symptoms of longest duration. Prolonged symptoms of anxiety and insomnia occurred in many who have discontinued benzodiazepines, including over 50% who were not originally prescribed benzodiazepines for that indication. It remains unclear if these symptoms might be caused by neuroadaptive and/or neurotoxic changes induced by benzodiazepine exposure. In this way, benzodiazepine withdrawal may have acute and long-term symptoms attributable to different underlying mechanisms, which is the case with alcohol withdrawal. Conclusions: These findings tentatively support the notion that symptoms which are acute but transient during benzodiazepine tapering and discontinuation may be distinct in their nature and duration from the enduring symptoms experienced by many benzodiazepine users.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with other published studies and clinical observations, this scoping review showed that some people can discontinue benzodiazepines even after prolonged exposure with relatively little problem [12,13,23].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Protracted symptoms persist beyond the expected elimination of the BZD from a patient’s system after discontinuation (e.g., 4–6 weeks), with some patients experiencing these symptoms for months or years.78,130,132”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [132]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A more prolonged condition had been observed decades ago, which typically can be identified after the acute withdrawal syndrome had abated, although nomenclature was inconsistent [23].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of pharmacology : the pathophysiologic basis of drug therapy
Golan, D. E., & Tashjian, A. H. (2012) · Cited by 469
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
The role of thiamine deficiency in alcoholic brain disease.
Martin, P., Singleton, C. K., & Hiller-Sturmhöfel, S. (2003) · Europe PMC (PubMed Central) · Cited by 381
Self-citationWithdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Withdrawal reactions from chlordiazepoxide (?Librium?)
Hollister, L. E., Motzenbecker, F. P., & Degan, R. O. (1961) · Psychopharmacologia · doi:10.1007/bf00429621 · Cited by 340 · cited 1×
“The majority of those who discontinued benzodiazepines reported experiencing the same four symptoms: (1) nervousness, anxiety, fear; (2) sleep disturbances; (3) difficulty focusing, distractedness; and (4) low energy.”
BackgroundBenzodiazepine Dependence A Review of the Evidence
Owen, R. T., & Tyrer, P. (1983) · Drugs · doi:10.2165/00003495-198325040-00003 · Cited by 287
The benzodiazepine withdrawal syndrome
PÉTURSSON, H. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03743.x · Cited by 246
The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis
Crowe, S. F., & Stranks, E. K. (2018) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acx120 · Cited by 209
Lobo, I. A., & Harris, R. A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.03.006 · Cited by 198
Research works printed but not linked: 6
- Janhsen K, 2015, Dtsch Arztebl Int, 112, 1
- Saitz R., 1998, Alcohol Health Res World, 22, 5
- Sachdeva A, 2015, J Clin Diagn Res, 9
- Martin PR, 2003, Alcohol Res Health, 27, 134
- 10.1111/j.1530-0277.2002.tb02681.x · doi:10.1111/j.1530-0277.2002.tb02681.x · Paper page
- Tyrer P., 1993, Biochem Soc Symp, 59, 107
Cited by
Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“78,130,132 Protracted withdrawal symptoms can adversely affect patients’ relationships, family life, careers, and mental health.”
Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey
Ritvo, A. D., Foster, D. E., Huff, C., Finlayson, A. J. R., Silvernail, B., & Martin, P. R. (2023) · PLOS ONE · doi:10.1371/journal.pone.0285584 · Cited by 38
“These findings and the results of our earlier reports [9, 10] conflict with some of the literature [11].”
ResultSelf-citationMoncrieff, J., Read, J., & Horowitz, M. A. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100765 · Cited by 20
Lynch, T., Ryan, C., Huff, C., Foster, D. E., & Cadogan, C. (2024) · Health Expectations · doi:10.1111/hex.13962 · Cited by 11
“30 In light of the potential for protracted withdrawal symptoms resulting from BZRA use, a team of experts representing academic, clinical and lived experience of BZRA discontinuation has proposed the term ‘ Benzodiazepine ‐ Induced Neurological Dysfunction ’ , which is defined as ‘ a constellation…”
BackgroundSelf-citation
Metadata
- Authors
- Huff, C., Finlayson, A. J. R., Foster, D. E., & Martin, P. R.
- Affiliations
- Benzodiazepine Information Coalition, 1042 Ft. Union Blvd., PMB 1030, Midvale, UT, 84047 USA
- Vanderbilt University Medical Center (US)
- Benzodiazepine Action Work Group, Colorado Consortium for Prescription Drug Abuse Prevention, Aurora, CO, USA
- Corresponding author
- Huff, Christy
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2023-01
- Volume
- 13
- Pages
- 20451253221145561-20451253221145561
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC9905027
- OpenAlex
- W4319316145
- Cited by
- 18
- References
- 38
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 8 · 2023: 2
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepine withdrawal, benzodiazepine tapering, benzodiazepine discontinuation, anxiety, insomnia, memory loss, neural adaptation, neurotoxicity, hallucinations, seizures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enduring neurological sequelae of benzodiazepine use: an Internet survey. https://app.cochat.ai/papers/10.1177/20451253221145561
- The paper
- Huff, C., Finlayson, A. J. R., Foster, D. E., & Martin, P. R. (2023). Enduring neurological sequelae of benzodiazepine use: an Internet survey. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253221145561
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.